CDC Guidance

NYS DOH Guidance

DOH’s COVID-19 Testing page covers Mobile Testing and testing protocols. Testing is free to all eligible New Yorkers as ordered by a health care provider or by calling the NYS COVID-19 hotline at 1-888-364-3065.

DOH has requested that hospitals submit a spreadsheet with race information for all patients who have expired to date due to COVID-19. Please e-mail for a copy of the spreadsheet and to submit information.

Item Date Updated
Required information for infectious diseases requisition 4/10
Specimen collection handling and transport instructions 3/20
Packaging and transport instructions 3/20
Novel Coronavirus Briefing: Governor Cuomo Announces State is Partnering with Hospitals to Expand Testing Capacity in New York 3/2
Current Status of SARS-CoV-2 Serologic Testing 4/22
Updated Interim Guidance: Protocol for COVID-19 Testing Applicable to All Health Care Providers and Local Health Departments 4/26
COVID-19 Serology Testing: Addresses the validation and approval of serology tests by the FDA and the use of serology tests at the point of care; clarifies the New York State Education Department requirements and the New York State testing protocol and provides FAQs and answers about serology testing to assist health care providers in their discussions with patients 4/30
New Hospital Reporting Requirements for Pediatric Multi-System Inflammatory Syndrome Potentially Associated with COVID-19 in Children: Reminds hospitals that have Pediatric Intensive Care Units or pediatric beds that the facility must complete reporting each day even if the facility has no patients who meet the PMIS case definition. 5/17
Specimen Collection Training for Unlicensed Individuals: Provides a protocol for COVID-19 testing in support of Executive Order 202.24 to authorize licensed pharmacists to order COVID-19 tests approved by the FDA to detect SARS-CoV-2 or its antibodies. 5/15
SARS-CoV-2 Point of Care (POC) Antigen Tests Frequently Asked Questions for Health Care Providers 10/17

NJ DOH Guidance

NYC DOHMH Guidance

Item Date Updated
Health Alert #3: Notifies health care providers that DOHMH can now perform COVID-19 testing at its PHL, which expands the availability of testing for New York City patients; clarifies new CDC testing criteria 3/4
Health Alert #11: Discusses limitations of current serologic tests to detect SARS-CoV-2 antibodies and recommends against the use of such tests for diagnosis or determining enduring immunity 4/22
Health Alert #12: Reports that the New York City Public Health Laboratory will begin accepting nasal swabs and saliva with nasopharyngeal swabs for COVID-19 testing to confirm the sensitivity of these less-invasive specimens. Once sensitivity is confirmed, patients may be able to self-collect these specimens, reducing the need for direct collection of specimens for testing by health care workers and the associated PPE required for such collection. 4/27
Health Alert #13: Issued in regards to the pediatric multisystem inflammatory syndrome that is potentially associated with COVID-19. Health care providers are asked to immediately report cases to the DOHMH Provider Access Line at 866-692-3641 if they meet the following criteria:

  1. patient is less than 21 years old, with persistent fever (four or more days), and either incomplete Kawasaki disease, typical Kawasaki disease, and/or toxic shock syndrome-like presentation; and
  2. no alternative etiology identified that explains the clinical presentation (note: patients should be reported regardless of the SARS-CoV-2 polymerase chain reaction test result)
Health Alert #15: Issued with updated recommendations for identifying and testing patients with suspected COVID-19. Updates include expanding testing to all people who are symptomatic, close contacts with or without symptoms of a person with confirmed COVID-19, and congregate residential-setting staff with or without symptoms. 5/15
Health Alert #16: Updated Reporting Requirements for Multisystem Inflammatory Syndrome in Children Associated with COVID-19 5/18
Health Advisory #37: All Point-of-Care COVID-19 Test Results Must be Reported Electronically 9/18

Important COVID-19 Lab Information

As of March 9, the New York City Public Health Laboratory is able to test combined nasopharyngeal (NP) and oropharyngeal (OP) swabs. Please place both NP and OP swabs in the same VTM tube and submit as one specimen with one form. Please contact the DOHMH Provider Access Line at (866) 692-3641 with questions.

Some New York City hospitals have been experiencing long delays in having specimens picked up by the New York City Public Health Lab (PHL). To mitigate this, the PHL will allow hospitals to bring specimens directly to the lab for processing. Hospitals should follow all regular specimen collection and packaging procedures.

Executive Order 202.24

On April 24, 2020, New York Governor Andrew Cuomo issued Executive Order (EO) 202.24, which granted pharmacists additional operational capacity in response to the COVID-19 public health emergency. Specifically, EO 202.24 allows licensed pharmacists to order Food and Drug Administration (FDA)-approved COVID-19 detection and/or FDA-approved antibody tests and administer them for patients suspected of having or having recovered from COVID-19. Additionally, the order allows the designation of pharmacists as qualified health professionals for the purpose of directing a limited service laboratory to test suspected COVID-19 patients, including antibody testing, provided such tests are FDA-approved and waived for use in a limited service laboratory.

CMS Tool Outlines Testing Requirements for SARS-COV-2

The CMS released a new tool for Clinical Laboratory Improvement Amendment (CLIA)-certified laboratories that are conducting tests for SARS-COV-2. The tool details types of SARS-COV-2 testing and FDA authorization/notification, CLIA certifications under which each test can be performed, an explanation of requirements under each testing scenario, and information for Medicare beneficiaries on testing services and coverage.

HHS Laboratory Reporting Guidance

The US Department of Health and Human Services (HHS) issued new guidance for laboratories to include additional patient data in their regular data submission to HHS on COVID-19 test results. New demographic data fields include race, ethnicity, age, and sex, and there are additional questions such as whether this is the patient’s first test, if the patient is employed in health care, if the patient lives in a congregate care setting, and if the patient is pregnant, among others. HHS is requiring that all data be reported via existing public health data reporting methods. HHS also provides a FAQ document.